The Uncharted, Uncertain Future of HOPE VI Redevelopments: The Case for Assessing Project Sustainability

Discusses the need for a third-party assessment of the management and financial stability issues posed by the publicly and privately funded redevelopment of housing projects into mixed-income, mixed-tenure properties. Explores feasibility at two sites

Young Patient Education on Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a genetic disorder that primarily causes the degeneration of major muscle groups. It’s caused by the absence of an essential sarcolemma protein called Dystrophin due to mutations in its gene that is in the X-chromosome. DMD affects 1 out of 4,000 boys worldwide with most being diagnosed between ages 3-5 and if left untreated, most patients would succumb to the disorder by their late teens or early twenties. While there currently isn’t a cure for DMD, there are different treatments available that are effective in prolonging patients’ lives. Because DMD is such a deadly disorder, it is important for current and future patients to understand their disorder as soon as possible in order to prepare themselves for whatever the future may hold for them. Currently, there are many information resources about the disorder online. However, most of this information caters to adult audiences, like the parents of DMD patients, and there are very few that cater specifically to the young patients themselves. For this reason, I created an animated educational video about DMD for young patients, so they would be properly educated about the disorder

The Effects of Mothers' Depression on the Behavioral Assessment of Disruptive Child Behavior

This study uses a group design to compare depressed and non-depressed mothers and their disruptive children. It controls for broad environmental stress factors to examine whether specific differences between groups can be linked with mothers’ depression. It aims to build a more comprehensive picture of depressed mothers’ interactions with their disruptive children by comparing these interactions with those of similar, but non-maternally depressed mother-child dyads, and a non-clinic control group

Low-dose (0.01%) atropine eye drops to reduce progression of myopia in children: a multi-centre placebo-controlled randomised trial in the United Kingdom (CHAMP-UK) – study protocol

Background/aims To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children. Methods Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6–12 years with myopia of −0.50 dioptres or worse in both eyes. We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms. The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events. Conclusions The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population. Trial registration number ISRCTN99883695 , NCT0369008

Treatment of depressed mothers with disruptive children: A controlled evaluation of cognitive behavioral family intervention

This study compared the effects of two forms of behavioral family intervention in reducing mothers' depression and disruptive behavior problems in families with a clinically depressed parent and a child with significant conduct problems. Fortyseven parents were randomly assigned to either a Behavioral Family Intervention (BFI) or to Cognitive Behavioral Family Intervention (CBFI) which integrated cognitive therapy strategies to treat depression and teaching of parenting skills. Both treatments were equally effective in reducing mothers' depression and child disruptive behavior on observational and self-report measures at postintervention. However, at 6-month follow-up more families in CBFI (53%) compared to BFI (13%) experienced concurrent clinically reliable reductions in maternal depression and child disruptive behavior. These findings support the value of CBFI in reducing depression in mothers of children with disruptive behavior problems

Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol

Background/aims: To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children. Methods: Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6–12 years with myopia of −0.50 dioptres or worse in both eyes. We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms. The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events. Conclusions: The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population